Solubilization and immunopurification of rat brain synaptic vesicle protein 2A with maintained binding properties

Neuroscience Letters

Volumn 398, Issue 1-2, 2006, Pages 107-112

  Lambeng, N ^a   Grossmann, M ^a   Chatelain, P ^a   Fuks, B ^a  

^a UCB PHARMA   (Belgium)

Author keywords

Immunopurification; N dodecyl d maltoside; Protein partners; Solubilization; SV2A

Indexed keywords

2 [4 (3 AZIDOPHENYL) 2 OXOPYRROLIDIN 1 YL]BUTANAMIDE; ANTICONVULSIVE AGENT; DETERGENT; ETIRACETAM; N DODECYL BETA DEXTRO MALTOSIDE; PROTEIN; SYNAPTIC VESICLE 2A PROTEIN; SYNAPTIC VESICLE 2C PROTEIN; SYNAPTOTAGMIN; UCB 30889; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; BRAIN MEMBRANE; DRUG POTENCY; IMMUNOPRECIPITATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; RAT; SCATCHARD PLOT; SOLUBILIZATION; STEREOCHEMISTRY;

ANIMALS; AZIDES; BINDING, COMPETITIVE; CEREBRAL CORTEX; GLUCOSIDES; IMMUNOPRECIPITATION; MEMBRANE GLYCOPROTEINS; MEMBRANES; NERVE TISSUE PROTEINS; PROTEIN ISOFORMS; PYRROLIDINES; RADIOLIGAND ASSAY; RATS; SURFACE-ACTIVE AGENTS; TRITIUM;

EID: 33646180878     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2005.12.059     Document Type: Article

References (31)

1. Bajjalieh S.M., Rantz G.D., Weimann J.M., McConnell S.K., and Scheller R.H. Differential expression of synaptic vesicle protein 2 (SV2) isoforms. J. Neurosci. 14 (1994) 5223-5235
2. Bajjalieh S.M., Peterson K., Linial M., and Scheller R.H. Brain contains two forms of synaptic vesicle protein 2. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 2150-2154
3. Bajjalieh S.M., Peterson K., Shinghal R., and Scheller R.H. SV2, a brain synaptic vesicle protein homologous to bacterial transporters. Science 257 (1992) 1271-1273
4. Bennett M.K., Calakos N., Kreiner T., and Scheller R.H. Synaptic vesicle membrane proteins interact to form a multimeric complex. J. Cell Biol. 116 (1992) 761-775
5. Buckley K., and Kelly R.B. Identification of a transmembrane glycoprotein specific for secretory vesicles of neural and endocrine cells. J. Cell Biol. 100 (1985) 1284-1294
6. i increase induced by ATP and bradykinin in PC12 cells. J. Pharm. Exp. Ther. 313 (2005) 720-730
7. Cheng Y., and Prusoff W.H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22 (1973) 3099-3108
8. Crowder K.M., Gunther J.M., Jones T.A., Hale B.D., Zhang H.Z., Peterson M.R., Scheller R.H., Chavkin C., and Bajjalieh S.M. Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 15268-15273
9. Engel C.K., Chen L., and Privé G.G. Stability of the lactose permease in detergent solutions. Biochim. Biophys. Acta 1564 (2002) 47-56
10. Feany M.B., Lee S., Edwards R.H., and Buckley K.M. The synaptic vesicle protein SV2 is a novel type of transmembrane transporter. Cell 70 (1992) 861-867
11. Fuks B., Gillard M., Michel P., Lynch B., Vertongen P., Leprince P., Klitgaard H., and Chatelain P. Localization and photoaffinity labelling of the levetiracetam binding site in rat brain and certain cell lines. Eur. J. Pharmacol. 478 (2003) 11-19
12. 3H]ucb 30889 to levetiracetam binding sites in rat brain. Eur. J. Pharmacol. 478 (2003) 1-9
13. Hammond J.R., and Zarenda M. Effect of detergents on ligand binding and translocation activities of solubilized/reconstituted nucleoside transporters. Arch. Biochem. Biophys. 332 (1996) 313-322
14. Herdon H.J., Godfrey F.M., and Chan W.N. Use of the radioligand [(125)I]-SB-217644 in the characterisation and solubilization of the novel binding site for the anticonvulsant SB-204269 in rat brain membranes and cell lines. Neuropharmacology 39 (2000) 2457-2463
15. Hovinga C.A. Levetiracetam: a novel antiepileptic drug. Pharmacotherapy 21 (2001) 1375-1388
16. 2+ regulators in neurotransmitter release. Neuron 24 (1999) 1003-1016
17. Janz R., and Sudhof T.C. SV2C is a synaptic vesicle protein with an unusually restricted localization: anatomy of a synaptic vesicle protein family. Neuroscience 94 (1999) 1279-1290
18. Klitgaard H., Matagne A., Gobert J., and Wulfert E. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur. J. Pharmacol. 353 (1998) 191-206
19. Lazzell D.R., Belizaire R., Takhur P., Sherry D.M., and Janz R. SV2B regulates synaptotagmin 1 by direct interaction. J. Biol. Chem. 279 (2004) 52124-52131
20. Lemieux M.J., Reithmeier R.A., and Wang D.N. Importance of detergent and phospholipid in the crystallization of the human erythrocyte anion-exchanger membrane domain. J. Struct. Biol. 137 (2002) 322-332
21. Lynch B.A., Lambeng N., Nocka K., Kensel-Hammes P., Bajjalieh S.M., Matagne A., and Fuks B. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 9861-9866
22. McKernan R.M., Castro S., Poat J.A., and Wong E.H. Solubilization of the N-methyl-d-aspartate receptor channel complex from rat and porcine brain. J. Neurochem. 52 (1989) 777-785
23. Margineanu D.G., and Klitgaard H. Inhibition of neuronal hypersynchrony in vitro differentiates levetiracetam from classical antiepileptic drugs. Pharmacol. Res. 42 (2000) 281-285
24. Margineanu D.G., and Klitgaard H. In: Levy R.H., Mattson R.H., Meldrum B.S., and Perucca E. (Eds). Antiepileptic drugs. fifth ed. (2002), Lippincott Williams and Wilkins, Philadelphia 419-427
25. Molinoff P.B., Wolfe B.B., and Weiland G.A. Quantitative analysis of drug-receptor interactions. II. Determination of the properties of receptor subtypes. Life Sci. 29 (1981) 427-443
26. Niespodziany I., Klitgaard H., and Margineanu D.G. Desynchronizing effect of levetiracetam on epileptiform responses in rat hippocampal slices. Neuroreport 14 (2003) 1273-1276
27. Pyle R.A., Schivell A.E., Hidaka H., and Bajjalieh S.M. Phosphorylation of synaptic vesicle protein 2 modulates binding to synaptotagmin. J. Biol. Chem. 275 (2000) 17195-17200
28. Schivell A.E., Batchelor R.H., and Bajjalieh S.M. Isoform-specific, calcium-regulated interaction of the synaptic vesicle proteins SV2 and synaptotagmin. J. Biol. Chem. 271 (1996) 27770-27775
29. Schivell A.E., Mochida S., Kensel-Hammes P., Custer K.L., and Bajjalieh S.M. SV2A and SV2C contain a unique synaptotagmin-binding site. Mol. Cell. Neurosci. 29 (2005) 56-64
30. Son Y.J., Scranton T.W., Sunderland W.J., Baek S.J., Miner J.H., Sanes J.R., and Carlson S.S. The synaptic vesicle protein SV2 is complexed with an alpha5-containing laminin on the nerve terminal surface. J. Biol. Chem. 275 (2000) 451-460
31. Xu T., and Bajjalieh S.M. SV2 modulates the size of the readily releasable pool of secretory vesicles. Nat. Cell Biol. 3 (2001) 691-698